Petrovax Pharm expands product portfolio with Demefecil, a combined medication used to treat rhinitis in adults and children from 1 year old

In August, the biotechnology company Petrovax Pharm introduced the new product Demefecil to its portfolio; it is a medicinal product used for the complex treatment of rhinitis.

Demefecil is a combination of the antiallergic component dimetindene and the mild vasoconstrictor phenylephrine. The medicinal product is available in the form of nasal drops.

Both components act gently and help accelerate the mucous membrane healing process in adults and children from 1 year old. Dimetindene alleviates allergy symptoms such as rhinorrhea, itching, sneezing, while phenylephrine relieves nasal congestion and swelling of the nasal mucosa and paranasal sinuses.[1][2]

The medicinal product is indicated for acute, allergic, vasomotor, and chronic rhinitis, acute and chronic sinusitis, as well as a supplementary aid in case of acute otitis media. Moreover, the combination of phenylephrine and dimetindene is recognized in the clinical guidelines for the treatment of allergic rhinitis of the Ministry of Health of the Russian Federation.[3]

Acute rhinitis is one of the most common diseases of the nasal mucosa that occurs concurrently with a bacterial or viral infection or an allergic process. Patients present with symptoms such as congestion, swelling of the nasal mucosa, itching, sneezing attacks, and hyposmia. According to statistics, allergic rhinitis affects 10-15 % of children aged 3 to 12 years.[4] The disease may be both seasonal and year-round.

Demefecil has taken its well-warranted place in Petrovax Pharm’s ENT and pediatric cold-relief portfolio. At present, the company can offer doctors a comprehensive pathogenetic and symptomatic therapy for upper respiratory tract diseases.

1 Geppe N.A., Starostina L.S., Batyreva O.V. Selection of rational methods for the therapy of mild to moderate acute infectious and persistent allergic rhinitis in children with computer bronchophonography. Attending physician 2010.N 10. -PP.92-96.

2 Maranta CA, Simmen D. Abschwellende Nasensprays. Ergebnisse einer rhinomanometrisch objektivierten, doppelblind durchgeführten Studie [Decongestant nasal spray. Results of a rhinomanometric double blind study]. Schweiz Med Wochenschr.1996 Nov 2; 126 (44):1875-80. German. Erratum in: Schweiz Med Wochenschr 1996 Nov 30; 126 (48):2104. PMID: 8984600.


4 Therapy for persistent allergic rhinitis in pediatric patients / E. P. Karpova [et al.] // Attending physician. - 2010. - No. 6. - PP. 86-88. Therapy for persistent allergic rhinitis in pediatric patients | #06/10 | Attending physician is a professional medical publication for physicians. Scientific articles. (

Previous news

Petrovax Pharm Team Expresses Sincere Condolences Regarding the Death of Company's Founder Arkady Nekrasov